News

Combination treatment with the novel adoptive Natural Killer-Like T (NK-T) cell therapy CRX100 and a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in a small cohort of patients with recurrent, platinum-resistant ovarian cancer, according to data from a phase 1 trial (NCT04282044) presented at the 2024 SGO...

19 March, 2024

Mahmoud Mahmoudian, Ph.D.,FRSC, Joins BioEclipse Board; Biopharmaceutical Industry Veteran with Proven Track Record in R&D, Venture Investments, and Business Development Stephen Ghiglieri, Managing Director at Danforth Advisors, to Serve as Interim CFO   MOUNTAIN VIEW, Calif., Jan. 26, 2022 /PRNewswire/ --  BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing...

26 January, 2022

Best StartUp - This article showcases our top picks for the best San Francisco based Therapeutics companies. These startups and companies are taking a variety of approaches to innovating the Therapeutics industry, but are all exceptional companies well worth a follow. We tried to pick companies across the size spectrum from cutting...

07 January, 2022

StartUp Insights - Global Startup Heat Map highlights 5 Top Startups tackling Ovarian Cancer out of 140   The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2.093.000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies &...

04 January, 2022

First-in-Human Trial to Enroll Up to 24 Patients with Refractory Solid Tumors   MOUNTAIN VIEW, Calif., Jan. 19, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz. for a Phase 1 dose-escalation trial to...

19 January, 2021

BioEclipse Therapeutics™ today announced today the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors. The trial marks the first-in-human study of CRX100, an intravenously-delivered cancer therapy designed to target and destroy multiple cancer types and address disease recurrence....

21 December, 2020

BioEclipse Therapeutics CEO Dr. Pam Contag, shares with Dan Levine, host of The Bio Report, about the ability of cancers to return after treatment with immunotherapies, BioEclipse’s efforts to develop a multi-mechanistic immunotherapy to overcome that challenge, and why its approach may have broad application across a range of cancers....

22 October, 2020
Show more
Loading...